INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2020

Weekly oral fecal microbiota transplantation from lean donors did not significantly improve insulin sensitivity or body composition in adults with obesity.

In a 12-week pilot trial, 24 adults with obesity and mild-moderate insulin resistance were randomized to weekly oral FMT capsules from healthy lean donors or placebo for 6 weeks. There were no statistically significant improvements in insulin sensitivity between groups (+5% ± 12% in FMT vs -3% ± 32% in placebo, mean difference 9%, 95% CI -5% to 28%, p = 0.16). Additionally, no significant differences were seen for HOMA-IR (mean difference 0.2, 95% CI -0.9 to 0.9, p = 0.96), lean mass (mean difference -0.1 kg, p = 0.87), or fat mass (mean difference 1.2 kg, p = 0.18). Variable bacterial engraftment persisted throughout 12 weeks with no serious adverse events related to FMT.

Study type
Randomized double-blind placebo-controlled pilot trial
Who was studied
24 adults with obesity and mild-moderate insulin resistance
What was measured
Change in insulin sensitivity (hyperinsulinemic euglycemic clamps) and metabolic markers

THE PAPER

Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial.

Yu EW, Gao L, Stastka P, Cheney MC, Mahabamunuge J, Torres Soto M, Ford CB, Bryant JA, Henn MR, Hohmann EL. PLoS Med, 2020.

PubMed 32150549 ↗DOI 10.1038/ijo.2017.220 ↗

Diabetes & blood sugarGut & microbiomeWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.